Form 4: Arcutis Legal Chief Reports Stock Grants, Sales

Arcutis Biotherapeutics' EVP and Chief Legal Officer, Masaru Matsuda, reported the acquisition of new restricted stock units and stock options, alongside sales of common stock, some for tax obligations.

Summary

• Masaru Matsuda, EVP, Chief Legal Officer of Arcutis Biotherapeutics, Inc., reported several transactions.
• Acquired 37,000 Restricted Stock Units (RSUs) on February 27, 2026, which vest 25% annually starting March 1, 2027, subject to continued service.
• Acquired 97,000 stock options on February 27, 2026, with an exercise price of $26.97, vesting 1/48th monthly from March 1, 2026, fully vested on the fourth anniversary, subject to continued service.
• Sold 3,325 shares of common stock at $27.95 on February 27, 2026, under a 10b5-1 trading plan adopted on June 5, 2025.
• Sold 6,553 shares of common stock at a weighted average price of $25.1604 (ranging from $24.69 to $25.70) on March 2, 2026, to cover tax withholding obligations related to RSU vesting.
• Sold 193 shares of common stock at a weighted average price of $25.9139 (ranging from $25.71 to $26.10) on March 2, 2026, also for tax withholding.
• Sold 1,987 shares of common stock at $25.70 on March 2, 2026, under the same 10b5-1 trading plan.
• Following these transactions, Matsuda beneficially owns 136,932 shares of common stock and 97,000 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive report. While there are sales of common stock, a significant portion is for tax withholding, and other sales are under a pre-arranged 10b5-1 plan. The grants of RSUs and stock options demonstrate continued executive incentive alignment.

Positives

• Grant of 37,000 Restricted Stock Units (RSUs) to the EVP, Chief Legal Officer, aligning executive interests with shareholder value.
• Grant of 97,000 stock options with an exercise price of $26.97, providing potential future upside for the executive and further aligning incentives.

Negatives

• Sales of common stock totaling 12,058 shares, including 6,746 shares specifically to cover tax withholding obligations, which reduces direct ownership.
• The remaining sales of 5,312 shares were part of a pre-arranged 10b5-1 plan, indicating a planned reduction in holdings.

Future Outlook

NA

Management Comments

• "The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026."
• "The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving grants of equity awards, are common practice for executive compensation in the biotechnology sector, aiming to align management incentives with long-term company performance. Sales made under pre-arranged 10b5-1 plans or for tax withholding are generally viewed as less indicative of management's sentiment about the company's future prospects compared to discretionary, open-market sales.

Stakeholder Impact

• Shareholders: The grant of equity awards to a key executive aligns their interests with long-term shareholder value. Sales, even for tax, slightly reduce direct insider ownership.
• Employees: The equity grants are part of executive compensation, which can set a precedent or reflect the company's overall compensation strategy.

Next Steps

• The 10b5-1 trading plan will continue until its end date of September 4, 2026.
• Restricted Stock Units (RSUs) will begin vesting annually on March 1, 2027.
• Stock options will continue to vest monthly from March 1, 2026, over four years.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Masaru Matsuda, Insider Trading, Form 4, Restricted Stock Units, Stock Options, 10b5-1 Plan, Executive Compensation, Stock Sale, Tax Withholding